Search research articles
Contact Us
Filters
Showing results (111-120 of 176) with videos related to
Page
of 18
Sort By:
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Hepatology (Baltimore, Md.)
|
September 11, 2012
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness
Hamish A Innes, Sharon J Hutchinson, Stephen Barclay, et al.
Molecular and Cellular Biology
|
June 25, 2014
Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance
Paul J Meakin, Sudhir Chowdhry, Ritu S Sharma, et al.
Journal of Hepatology
|
May 13, 2022
Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557]
Alan Yeung, Norah E Palmateer, John F Dillon, et al.
Journal of Hepatology
|
October 11, 2021
Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
Alan Yeung, Norah E Palmateer, John F Dillon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 24, 2021
Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study
Hamish Innes, Scott A McDonald, Victoria Hamill, et al.
European Journal of Gastroenterology & Hepatology
|
December 24, 2015
The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort
Huan Wang, Hamish Innes, Sharon J Hutchinson, et al.
The International Journal on Drug Policy
|
May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK
Zoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Gastro Hep Advances
|
August 12, 2024
Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making
Hamish Innes, Philip Johnson, Scott A McDonald, et al.
Addiction (Abingdon, England)
|
March 2, 2021
Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data
Norah E Palmateer, Andrew McAuley, John F Dillon, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 176) with videos related to
Sort By:
Page
of 18
The International Journal on Drug Policy
|
February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Jason Grebely, Gregory J Dore, Negar N Alami, et al.
Hepatology (Baltimore, Md.)
|
September 11, 2012
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness
Hamish A Innes, Sharon J Hutchinson, Stephen Barclay, et al.
Molecular and Cellular Biology
|
June 25, 2014
Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance
Paul J Meakin, Sudhir Chowdhry, Ritu S Sharma, et al.
Journal of Hepatology
|
May 13, 2022
Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557]
Alan Yeung, Norah E Palmateer, John F Dillon, et al.
Journal of Hepatology
|
October 11, 2021
Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
Alan Yeung, Norah E Palmateer, John F Dillon, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 24, 2021
Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study
Hamish Innes, Scott A McDonald, Victoria Hamill, et al.
European Journal of Gastroenterology & Hepatology
|
December 24, 2015
The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort
Huan Wang, Hamish Innes, Sharon J Hutchinson, et al.
The International Journal on Drug Policy
|
May 30, 2026
Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK
Zoe Ward, Hannah Fraser, Stuart Mc Pherson, et al.
Gastro Hep Advances
|
August 12, 2024
Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making
Hamish Innes, Philip Johnson, Scott A McDonald, et al.
Addiction (Abingdon, England)
|
March 2, 2021
Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data
Norah E Palmateer, Andrew McAuley, John F Dillon, et al.
Page
of 18